Detection of prevalence and severity of (subclinical) pulmonary artery emboli in the setting of COVID-19 disease using pulmonary ventilation/perfusion scintigraphy.
- Conditions
- I26Pulmonary embolism
- Registration Number
- DRKS00023606
- Lead Sponsor
- niversitätsklinikum Augsburg - Nuklearmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 6
Patients with condition after PCR-proven SARS-CoV-2 infection and again negative PCR after recovery, regardless of further therapeutic measures, if the patients had to undergo hospitalisation in connection with the SARS-CoV-2 infection.
1. pregnant or breastfeeding women
2. minors and patients with mental illness or such patients,
who are unable to give written informed consent to the study
3. haemodynamically unstable patients or patients with acute myocardial infarction (ST-segment elevation, creatinine kinase or MB isoenzyme elevation > 3 times the normal value)
4. bronchial asthma/COPD
5. known allergy to chicken egg white or charcoal
6. known cardiac right-to-left shunt
7. renal insufficiency (serum creatinine >2.0 mg/dl or GFR <30ml/min)
8. patients with claustrophobia
9. patients with previously diagnosed pulmonary artery embolism
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ventilation/perfusion scintigraphy of patients immediately after COVID 19 infection requiring hospital admission (1-2 weeks after negative throat swab/rinse PCR for SARS-CoV-2) and at 3 and 12 month intervals will be used to assess the frequency, time of manifestation and persistence, if any, of pulmonary artery emboli occurring in patients with COVID 19 infection.
- Secondary Outcome Measures
Name Time Method